CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Investor Relations  /  Stock Exchange Disclosures  /  Biocon Biologics SGX Disclosure

BIOCON BIOLOGICS SGX DISCLOSURE

FY 2025-26

Apr-26
07-Mar Biocon Announces U.S. Commercial Launch of Bosaya™ and Aukelso™, Denosumab Biosimilars
Mar-26
27-Mar Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
Feb-26
12-Feb Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr; Q3FY26 EBITDA at Rs 951 Cr; Q3FY26 Net Profit at Rs 144 Cr
Jan-26
28-Jan S&P Global Upgrades Biocon Biologics Credit Rating To ‘BB+’ Revises Outlook to “Stable”
06-Jan Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conferences
06-Jan Stock Exchange Disclosure in relation to Acquisition of equity shares of Biocon Biologics Limited and allotment of equity shares of Biocon Limited on a preferential basis
Dec-25
23-Dec Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
13-Dec Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
11-Dec S&P Global Places Biocon Biologics on Positive CreditWatch On Account of Accelerated Debt Reduction
06-Dec Outcome of Board Meeting under Regulation 30 of SEBI Listing Regulations, 2015.
06-Dec Biocon Limited to Integrate Biocon Biologics Limited to Create a Unified Global Biopharmaceutical Leader
Nov-25
27-Nov Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)
12-Nov Consolidated financial statements (‘financial statements’) of Biocon Biologics Limited (“the Company”) for the quarter and half year ended September 30, 2025.
11-Nov Press Release on Financial Results for the quarter ended September 30, 2025
Sep-25
04-Sep U.S. FDA Completes Inspection at Biocon Biologics’ Facility at Biocon Campus, Bengaluru, India
July-25
23-July Biocon Biologics Launches Nepexto®, a Biosimilar to Enbrel® (Etanercept), in Australia
15-July Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
07-July Biocon Biologics Receives MHRA, UK Approval for YESINTEK®, Biosimilar Ustekinumab
03-July Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars
June-25
30-Jun Biocon Biologics Expands Insulin Access in Malaysia
27-Jun Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025
24-Jun Biocon Biologics Collaborates with National Cancer Society Malaysia
May-25
25-May Biocon Biologics Receives MHRA, UK Approval for YESINTEK®, Biosimilar Ustekinumab
22-May Malaysian MoH Awards Insulins Supply Contract Extension to Biocon Biologics
21-May Biocon Biologics and Yoshindo Expand Access to Ustekinumab Biosimilar in Japan
09-May Consolidated financial statements (‘financial statements’) of Biocon Biologics Limited (“the Company”) for the quarter and year ended March 31, 2025.
08-May Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%
05-May Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
April-25
28-April Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
26-April Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
15-Apr Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
10-Apr Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

Know more
about us

>> Generics
>> Biocon Academy
>> Biocon Malaysia

NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2026, Biocon. All Rights Reserved
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>